Navigation Links
Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
Date:8/29/2007

that, while considered reasonable by us are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements, including, among others: our ability to obtain the capital required for research and operations, the inherent risks in early stage drug development including demonstrating efficacy, development time/cost and the regulatory approval process; the progress of our clinical trials; our ability to find and enter into agreements with potential partners; our ability to attract and retain key personnel; changing market conditions; and other risks detailed from time-to-time in our ongoing quarterly filings, annual information forms, annual reports and annual filings with Canadian securities regulators and the United States Securities and Exchange Commission.

Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled "Risk Factors" in our Annual Information Form underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. We cannot assure you that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.

Lorus Therapeutics Inc.'s recent press
'/>"/>

SOURCE Lorus Therapeutics Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. The Affymetrix GeneChip Scanner 3000 New Advances in Scanner Design for Superior Performance, Reliability, and Dynamic Range
2. Quintessence Biosciences advances cancer drug
3. Healthcare slow to adopt genetic advances
4. Wireless advances in Madison, heats up in Waukesha
5. GE Healthcares CT Scanner advances coronary imaging
6. Cancer treatment advances as trials show no harm to mice
7. New CT scanner by GE Healthcare advances imaging technology
8. Small wonders: Intersection of biotech and nanotech will produce big advances
9. Standards Needed for Advances in Healthcare Technology
10. BioRobot MDx standardize your automated protocols in clinical laboratories
11. What patients want: A story of choice, clinical trials & evidence-based medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... aids to weight loss and diabetes prevention, could actually ... and they do it in a surprising way: by ... the substantial population of bacteria residing in our ... and humans, were published today in Nature . ... Weizmann Institute,s Immunology Department, who led this research together ...
(Date:9/18/2014)... San Diego, CA (PRWEB) September 18, 2014 ... promotions which include Sartorius/Biohit, Socorex, Capp, and ... working with volumes of 100 uL or less ... pharmaceutical, oncology, and forensic applications. , The ... of high quality and economic alternative products to ...
(Date:9/17/2014)... global consumption of squalene / squalane is expected to be ... that finds applications in various end user industries such as ... applications like high grade lubrication, and fiber coating additives. ... is regionally segregated. Sophim ( France ), Amyris ... Japan ), SeaDragon Marine Oils Ltd. ( New ...
(Date:9/17/2014)... , Sept. 17, 2014  MiMedx Group, Inc. ... processor and marketer of patent protected regenerative biomaterials ... today the publication of another peer-reviewed clinical study.    ... A Multi-center Randomized Controlled Clinical Trial Evaluating the ... Membrane Allografts and Multi-layer Compression Therapy vs. Multi-layer ...
Breaking Biology Technology:Gut bacteria, artificial sweeteners and glucose intolerance 2Gut bacteria, artificial sweeteners and glucose intolerance 3Major Pipette Distributor Pipette.com Announces Promotions on Sartorius/Biohit, Socorex, Capp, and AccuPet Micropipettes 2Major Pipette Distributor Pipette.com Announces Promotions on Sartorius/Biohit, Socorex, Capp, and AccuPet Micropipettes 3Squalene Market by Source (Animal & Vegetable) & by End-user Industry (Cosmetics, Pharmaceuticals & Food Industry) - Global Trends & Forecasts to 2019 2Squalene Market by Source (Animal & Vegetable) & by End-user Industry (Cosmetics, Pharmaceuticals & Food Industry) - Global Trends & Forecasts to 2019 3MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 2MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 3MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 4
... 18 Volcano Corporation,(Nasdaq: VOLC ), ... measurement (FM) products designed to enhance the ... disease, announced today that it,has completed its ... CardioSpectra is a privately-held company developing innovative ...
... Dec. 18 Pharmos Corporation,(Nasdaq: PARS ) ... has elected,to resign from the Company., Mr. ... instrumental in the,strategic acquisition and the subsequent integration ... Vela acquisition,Mr. Rubino has been focused on key ...
... Vice President and General Manager of facility ... prescriptions a week, FRANKLIN LAKES, N.J., Dec. 18 ... nation,s leading pharmacy benefit,managers, today announced that AllPoints at Anson ... most-advanced automated pharmacy,capping a nearly year-long search that spanned 48 ...
Cached Biology Technology:Volcano Announces Closing of CardioSpectra Acquisition 2Volcano Announces Closing of CardioSpectra Acquisition 3Pharmos Corporation Announces President & COO Alan L. Rubino to Leave Company 2Medco Chooses AllPoints at Anson in Whitestown, Indiana as Site for the World's Largest, Most-Advanced Automated Pharmacy 2Medco Chooses AllPoints at Anson in Whitestown, Indiana as Site for the World's Largest, Most-Advanced Automated Pharmacy 3Medco Chooses AllPoints at Anson in Whitestown, Indiana as Site for the World's Largest, Most-Advanced Automated Pharmacy 4Medco Chooses AllPoints at Anson in Whitestown, Indiana as Site for the World's Largest, Most-Advanced Automated Pharmacy 5
(Date:9/17/2014)... four-year project, delivering its first release in 2004. After ... several EC projects, as a part of the EC-FP7 ... to increase the general awareness of the work done ... of the Fauna Europaea results, the Biodiversity ... tools to prepare data papers for all 56 major ...
(Date:9/17/2014)... Biomedical Informatics at IMIM (Hospital del Mar Medical Research ... have recently published a study in eLife ... role in the evolution of new proteins, some of ... discovered., Ribosomes produce proteins from the instructions found in ... genome is RNA containing information for the synthesis of ...
(Date:9/17/2014)... of researchers working on a Carnegie expedition in Australia,s ... have plummeted 40% since the mid-1970s. The scientists suggest ... in this perilous slowdown. , In a quest ... the team compared current measurements of the growth rate ... similar measurements taken more than 30 years ago. Their ...
Breaking Biology News(10 mins):Contributions on Fauna Europaea: Data papers as innovative model on expert involvement 2Parts of genome without a known function may play a key role in the birth of new proteins 2Coral growth rate plummets in 30-year comparison 2
... collaboration with scientists at the University of California, San Diego ... switch that plays a crucial role in the development of ... issue of the journal Molecular Cell, provide a template for ... a protein called Scp1, at will. , "Scp1 is an ...
... the reach of a novel genome mapping method ... and more cost-effective tool than traditional DNA sequencing. ... Michael Waterman, USC University Professor in molecular and ... the massive amounts of data created by a ...
... 2005, 40.3 million people in the world, including 25.8 million ... the origin of HIV-1, responsible for the AIDS pandemic, has ... months ago, the team of Martine Peeters, director of research ... unit UMR 145 jointly involving the IRD and the University ...
Cached Biology News:Detailed 3-D image catches a key regulator of neural stem cell differentiation in action 2Detailed 3-D image catches a key regulator of neural stem cell differentiation in action 3Powerful genome ID method extended to humans 2Wild gorillas carriers of a SIV virus close to the AIDS virus 2
... This DuoSet ELISA Development kit contains the ... sandwich ELISAs to measure natural and recombinant ... serum. Each kit contains sufficient materials ... plates, provided that the following conditions are ...
RABBIT ANTI PORCINE CARBOXYPEPTIDASE B...
Recombinant Ovine (Sheep) Growth Hormone, Ultra Pure...
Request Info...
Biology Products: